Guide

Losing Weight Slower Than Your Partner on the Same GLP-1

Trial averages hide enormous individual variation, and men and women lose at different rates for reasons that have nothing to do with dose being wrong. Comparing your tra

What a trial mean actually is

SURMOUNT-1 reported about 20.9% mean reduction at 15 mg. That average contains people who lost far more and people who lost very little. In the same trial, 50% and 57% of the 10 and 15 mg groups reached 20% or greater reduction — which means roughly half did not.

Two people on identical doses landing in different parts of that distribution is the expected result, not a malfunction.

Reasons two people diverge that are not about dose

• Starting weight and body composition. Percentage change and absolute change behave differently, and a larger starting weight often produces faster early absolute loss.
• Lean mass. Body-composition analyses put the lean-mass share of weight lost at roughly 20% to 40%, and baseline lean mass differs between people.
• Where each of you is in titration. Someone four weeks ahead is on a different curve.
• Menopausal status. Hormonal change affects body composition and weight independently of any medication.
• Other medications and conditions. Several common drug classes affect weight.
• Whether the preparations are identical. Compounded products vary in concentration between compounders and are not bioequivalence-tested. Two people on "the same medication" from different providers may not be on the same thing.

The comparison worth making instead

Your own trajectory over months, against the shape the trials show — steep early, flattening substantially in the second half. A slowdown after several months is the expected curve, not a failure.

When it is worth raising

1. No change at all after several weeks at a recommended maintenance dosage.
2. Side effects that are limiting your ability to escalate.
3. Weight rising steadily rather than plateauing.
4. A change coinciding with a new supplier or vial.

Those are clinical questions with individual answers. What is not useful is treating one other person's trajectory as your benchmark.

One thing worth naming

Comparing weight-loss progress with a partner can be corrosive well beyond the clinical question. If tracking against someone else's results is affecting how you eat or how you feel about yourself, that is worth mentioning to your clinician too — it is a legitimate part of the conversation, not a side issue.